Interleukin-18 (IL-18
The resistance and susceptibility of inbred strains of mice to infection with Leishmania major are intimately associated with their capacity to produce gamma interferon (IFN-␥) and interleukin-4 (IL-4), respectively (2, 3, 14, 15, 26, 36, 38, 39, 41) . Healing of lesions caused by L. major infection requires induction and expansion of T helper 1 (Th1) cells, which produce IFN-␥, a crucial activator of inducible nitric oxide synthase (iNOS) (5, 20, 23, 53) . In contrast, IL-4, produced by T helper 2 (Th2) cells, promotes disease, because IL-4 inhibits the expression of iNOS (25) . The importance of the nitric oxide (NO)-dependent killing of intracellular parasites was demonstrated (7, 9, 23, 24, 44) and was further substantiated by the result showing that iNOS-deficient mice with a resistant background developed nonhealing cutaneous lesions (7, 55) .
IL-12 is a major determinant of transformation of naive T cells into IFN-␥-producing Th1 cells in vitro (19, 32, 40, 48) . The essential role of IL-12 in Th1 cell development in vivo has been well established by using mice infected with L. major (17, 35, 52) . IL-12-deficient mice with a resistant background lack the Th1 responses (27) and suffer from progressive disease (29) . In complementary studies, injection of high doses (e.g., 200 ng) of IL-12 into nonhealing mice such as BALB/c mice could induce Th1 cells that produce IFN-␥ and allow the resolution of lesions (16, 45) , indicating that IL-12 is a powerful factor that modulates host immunity.
We and others have been interested in the elucidation of the mechanism by which IFN-␥ production is synergistically induced by the action of IL-12 and IL-18 in vitro and in vivo (22, 28, 33, 37, (56) (57) (58) (59) . IL-18, a product of activated macrophages and Kupffer cells, is a potent pleiotropic cytokine (8, 10, 34) . IL-18 induces IFN-␥ production by lymphocytes, such as T cells, B cells, and natural killer (NK) cells, particularly in a synergistic manner with IL-12 (22, 28, 33, 51, (57) (58) (59) (60) . IL-18 augments NK cell activity through the activation of constitutively expressed IL-18 receptor (IL-18R) on NK cells (21) . In addition, IL-18 up-regulates Fas ligand-mediated cytotoxic activity of cloned Th1 cells and NK cells (6, 49) . IL-18R, composed of IL-1R-related protein (IL-18R␣) (47) and accessory protein-like IL-18R␤ (4), belongs to the IL-1R family (8) . IL-18R␣ is the ligand-binding subunit of IL-18R (47), and IL-18R␤ is a signaling molecule (4) .
Recently, we and others reported that stimulation of naive T cells with IL-12 and antigen can induce Th1 cells that express IL-18R (56, 59) . Furthermore, we and other investigators reported that IL-18R is not expressed on Th2 cells, and thus IL-18 stimulates only Th1 cells to produce IFN-␥ (22, 37, 56, 59) . Since Th1 cells play a critical role in protection against L. major infection, we regarded it important to determine whether IL-18 plays an important role in host defense by activation of Th1 cells in vivo. Thus, we first tested the healinginducing activity of daily injection of IL-18 with or without IL-12 in L. major-susceptible BALB/c mice. We then investigated involvement of endogenous IL-18 in the host defense of L. major-resistant strains, such as C3H/HeN and C57BL/6 mice, by using anti-IL-18 antibody (Ab) treatment or IL-18-
RESULTS
Administration of the combination of IL-12 and IL-18 protects BALB/c mice from leishmaniasis. We first examined the capacity of IL-12 to induce IL-18R␣ expression in vivo. For this purpose, we daily injected BALB/c mice i.p. with IL-12 (10 to 1,000 ng/mouse) for 4 days. As shown in Fig. 1A , even a low dose of IL-12 (10 ng/mouse) could induce IL-18R␣ mRNA in CD4 ϩ T cells. Although neither IL-12 (10 to 1,000 ng/mouse) nor IL-18 (100 to 5,000 ng/mouse) induced increases in serum IFN-␥ and NO 2 Ϫ -NO 3 Ϫ levels, their combination caused striking increases in levels of IFN-␥ and NO 2 Ϫ -NO 3 Ϫ in serum in a dose-dependent manner (data not shown). Since 10 ng of IL-12 induced a substantial increase in IL-18R␣ mRNA in CD4 ϩ T cells (Fig. 1A) , we used this dose for coinjection. As shown in Fig. 1B , IL-18 dose-dependently induced increases in serum IFN-␥ and NO 2 Ϫ -NO 3 Ϫ levels. The maximal serum NO 2 Ϫ -NO 3 Ϫ level was seen in the mice administered 10 ng of IL-12 and 1,000 ng of IL-18. Therefore, we used 10 ng of IL-12 and 1,000 ng of IL-18 in the following experiments.
We next examined whether administration of IL-12 and IL-18 into BALB/c mice induces wound healing in an IFN-␥-dependent manner. BALB/c mice infected with L. major developed progressive disease, as assessed by footpad swelling (Fig. 1C) . Administration of 10 ng of IL-12 or 1,000 ng of IL-18 for the first week of infection did not inhibit this footpad swelling. However, administration of a mixture of IL-12 and IL-18 strongly protected the mice from footpad swelling (Fig.  1C) . We also examined the parasite burden at 8 weeks after infection. Consistent with a previous report (14) , the level of footpad swelling paralleled well the degree of parasite burden ( Fig. 1C and D) . Thus, IL-12 and IL-18 inhibited footpad swelling by significant killing (P Ͻ 0.001) of parasites in the macrophages.
Administration of the combination of IL-12 and IL-18 does not protect IFN-␥ ؊/؊ BALB/c mice from leishmaniasis. To examine whether IL-12 and IL-18 cure BALB/c mice by induction of IFN-␥ that kills L. major in an NO-dependent manner, we daily administered a mixture of IL-12 and IL-18 to IFN-␥ ϩ/ϩ and IFN-␥ Ϫ/Ϫ BALB/c mice during the first week after L. major infection. Infected IFN-␥ ϩ/ϩ mice manifested footpad swelling ( Fig. 2A) . Again, although neither IL-12 nor IL-18 inhibited this footpad swelling (data not shown), its combination strongly did ( Fig. 2A) . Furthermore, this treatment induced a marked increase in the serum NO 2 Ϫ -NO 3 Ϫ level in IFN-␥ ϩ/ϩ mice (Fig. 2B ), while treatment with IL-12 or IL-18 alone failed to do so (data not shown). We simultaneously treated L. major-infected IFN-␥ Ϫ/Ϫ mice with IL-12 and IL-18. Infected IFN-␥ Ϫ/Ϫ mice showed striking footpad swelling ( Fig.  2A) . Injection of IL-12 and IL-18 did not affect this footpad swelling ( Fig. 2A) , suggesting that IL-12 and IL-18 killed intracellular parasites via the action of IFN-␥. Moreover, this treatment failed to induce NO production in IFN-␥ Ϫ/Ϫ mice (Fig. 2B) . These results taken together indicate that IL-12 and IL-18 induced wound healing by induction and activation of Th1 cells that produce IFN-␥, leading to NO-dependent elimination of parasites.
BALB/c mice that recover from L. major infection due to treatment with IL-12 and IL-18 acquire protective immunity. Next, we examined whether treatment of L. major-infected mice with IL-12 and IL-18 can immunize them against reinfection. Thus, BALB/c mice that recovered from L. major infection after treatment with IL-12 and IL-18 were reinfected with 5 ϫ 10 6 stationary-phase promastigotes at 14 weeks after the first infection. We simultaneously compared the capacities of immunized BALB/c mice and L. major-resistant C3H/HeN mice to produce NO in response to infection. As shown in Fig.  3A , PBS-treated BALB/c mice manifested footpad swelling after infection with L. major, while immunized BALB/c mice were highly resistant. Importantly, these mice, like L. majorresistant C3H/HeN mice, had increased serum NO 2 Ϫ -NO 3 Ϫ levels after reinfection (Fig. 3B ). These results taken together strongly indicate that treatment with IL-12 and IL-18 not only cured primary infection but also provided protective immunity against reinfection. Anti-IL-18 Ab exacerbates L. major infection in C3H/HeN mice. Next, to address the role of endogenous IL-18 in the host defense of C3H/HeN mice, we injected anti-IL-18 Ab (200 g/mouse) twice a week immediately after infection with L. major. As shown in Fig. 4A , anti-IL-18 Ab treatment significantly reduced the host resistance to L. major infection (5 weeks after infection; P Ͻ 0.01). However, this effect was not persistent, and once the Ab treatment was stopped, these mice recovered from L. major infection.
To show that this prolonged footpad swelling seen with C3H/HeN mice treated with anti-IL-18 Ab was associated with a decrease in NO production, we simultaneously measured the serum NO 2 Ϫ -NO 3 Ϫ level. As expected, the serum NO 2 Ϫ -NO 3 Ϫ level in C3H/HeN treated with anti-IL-18 Ab was 2.6-fold lower than that in control C3H/HeN mice (Fig. 4B ). This effect was significant (2 weeks after infection; P Ͻ 0.01). We also measured the capacity of popliteal lymph node cells to produce IFN-␥ upon stimulation with SLA or ConA in vitro. As shown in those from BALB/c mice produced little IFN-␥ (Fig. 4C) . Thus, anti-IL-18 Ab treatment did not inhibit generation of Th1 cells in L. major-infected C3H/HeN mice. Furthermore, lymphocytes from the L. major-infected C3H/HeN mice with or without anti-IL-18 Ab treatment expressed IL-18R␣ mRNA equally, while those from BALB/c mice did not (Fig. 4D) , further substantiating previous reports that IL-18R␣ is preferentially expressed on Th1 cells (56, 59) .
Increased footpad swelling in IL-18 ؊/؊ mice. To further understand the protective role of endogenous IL-18, we examined IL-18 Ϫ/Ϫ mice (46) with a resistant background. Compared to IL-18 ϩ/ϩ C57BL/6 mice, IL-18 Ϫ/Ϫ C57BL/6 mice had sustained footpad swelling (Fig. 5A, upper panel) . They required 15 weeks to achieve complete lesion resolution (data not shown). Consistent with this long-lasting footpad swelling, the serum NO 2 Ϫ -NO 3 Ϫ level in IL-18 Ϫ/Ϫ mice was significantly lower (P Ͻ 0.01) than that in IL-18 ϩ/ϩ mice (Fig. 5A , lower panel). These results suggested that endogenous IL-18 may be required for shortening the duration of wound healing by increasing NO production. Indeed, administration of IL-18 (1,000 ng/mouse) to IL-18 Ϫ/Ϫ mice not only shortened this duration but also increased NO production (Fig. 5A) .
We simultaneously examined the involvement of IL-18 in generation of Th1 cells in L. major-infected mice (Fig. 5B) . Consistent with the results in Fig. 4C , lymphocytes from popliteal lymph nodes of BALB/c mice produced little IFN-␥ in response to ConA or SLA, although they strongly produced IL-4. In contrast, popliteal lymph node cells from both IL-18 ϩ/ϩ and IL-18 Ϫ/Ϫ mice similarly and dominantly produced IFN-␥ in response to ConA or SLA (Fig. 5B) 
DISCUSSION
In this study, we have shown that daily injection of IL-12 (10 ng/mouse) and IL-18 (1,000 ng/mouse) into L. major-susceptible BALB/c mice induces wound healing by induction and activation of Th1 cells, which also play a protective role in a subsequent infection with L. major. We also investigated a protective role of endogenous IL-18 by using anti-IL-18 Abtreated C3H/HeN mice or IL-18 Ϫ/Ϫ mice (C57BL/6 background). These mice showed prolonged footpad swelling and diminished NO production following L. major infection. Administration of IL-18 corrected these defects in IL-18 Ϫ/Ϫ mice, but the absence of IL-18 did not affect development of Th1 cells, suggesting that IL-18 is not responsible for inducing Th1 cells. However, the memory response to L. major infection was severely suppressed in IL-18 Ϫ/Ϫ mice, suggesting the importance of endogenous IL-18 for immunization and/or activation of memory cells.
Administration 20, 23). The importance of iNOS-directed NO production is demonstrated by the failure of iNOS-deficient mice to heal infection (7, 55 (56, 59) . Thus, we first determined the minimal dose of IL-12 required for induction of IL-18R␣ on T cells (Fig. 1A) , because daily injection of high doses of IL-12 is toxic to the host (13) . We found that daily injection of 10 ng of IL-12 (a nontoxic dose) into the mouse is sufficient for induction of IL-18R␣ (Fig. 1A) . Thus, we injected 10 ng of IL-12 and various doses of IL-18. In this report, we showed that administration of the combination of IL-12 (10 ng/mouse) and IL-18 (1,000 ng/mouse) to L. major-infected BALB/c mice strongly protected them from footpad swelling by killing parasites in macrophages ( Fig. 1C and D) . Since same treatment of IFN-␥ Ϫ/Ϫ BALB/c mice failed to induce wound healing ( Fig.  2A) , this protection is entirely dependent on the action of IFN-␥. Importantly, BALB/c mice that recovered from L. major infection after treatment with IL-12 and IL-18 became highly resistant to reinfection (Fig. 3A) , suggesting that these BALB/c mice were properly immunized against L. major infection. Indeed, similar to C3H/HeN mice, these BALB/c mice increased their serum NO 2 Ϫ -NO 3 Ϫ levels after reinfection (Fig. 3B ).
This treatment with IL-18 has several advantages. First, we could decrease the dose of IL-12 to the minimum that is required for induction of IL-18R. Second, IL-12 and IL-18 synergistically induce IFN-␥ production and subsequent NO production, providing the best stimulation for induction of production of NO, a lethal molecule for L. major. Third, injection of IL-18 without IL-12 could be used as an effective treatment of the hosts that have intact IL-12 production but lack IL-18 production. Fourth, treated mice become healthy and resistant to reinfection. We could assume that IL-18, combined with CD4
ϩ -T-cell depletion, IL-4 neutralization, and intralesion IL-12 (18) , may provide us with a highly effective means for the treatment of advanced leishmaniasis.
It has been demonstrated that BALB/c mice vaccinated with either SLA or single parasite leishmania homolog of receptors for activated C kinase (LACK) protein in the presence of IL-12 are protected from subsequent challenge with L. major in a Th1-dependent manner (1, 30) . Gurunathan et al. reported that vaccination with DNA encoding the immunodominant LACK parasite antigen can elicit prolonged protective immunity to L. major in an IL-12-and IFN-␥-dependent manner (11, 12) . Recombinant leishmania protein (LeIF) has been shown to stimulate the Th1 response and protect BALB/c mice from L. major in an IL-12-and IL-18-dependent manner (42) . From these results, LACK DNA may stimulate macrophages to produce IL-12 and IL-18. Thus, administration of IL-12 and IL-18 provides us with good means for the treatment of L. major infection. Furthermore, this combination of IL-12 and IL-18 with proper leishmanial antigens may allow us to rationally design L. major vaccination.
Role of endogenous IL-18 in host resistance to L. major infection. Recently, IL-18 Ϫ/Ϫ mice were shown to display reduced production of IFN-␥, impaired NK cell activity, and defective Th1 cell development in response to bacillus CalmetteGuérin (Mycobacterium bovis BCG) (46) . Therefore, it is important to examine the involvement of endogenous IL-18 in the development of Th1 cells in L. major-resistant C3H/HeN mice or C57BL/6 mice after infection.
Administration of neutralizing anti-IL-18 Ab to C3H/HeN mice reduced their resistance by down-regulation of IFN-␥-mRNA expression in their lymph node cells (data not shown) and subsequent IFN-␥-dependent NO production ( Fig. 4A and  B) , suggesting that endogenous IL-18 is critically involved in up-regulation of IFN-␥-mRNA expression. However, this effect was only transient. When injection of anti-IL-18 Ab was stopped, these anti-IL-18 Ab-treated C3H/HeN mice quickly recovered from infection (Fig. 4A) . This Ab treatment did not inhibit development of Th1 cells, because lymphocytes from 
L. major-infected C3H/HeN mice with or without anti-IL-18
Ab treatment produced IFN-␥ equally in response to SLA or ConA (Fig. 4C) . Furthermore, they equally expressed IL-18R␣ chain mRNA (Fig. 4D ), a Th1 cell marker (56, 59) , while lymphocytes from L. major-infected BALB/c mice did not express IL-18R␣ mRNA. Thus, even in anti-IL-18 Ab-treated C3H/HeN mice, these Th1 cells can produce IFN-␥ in response to antigens derived from L. major plus IL-12 in vivo, leading to induction of production of low levels of NO (Fig.  4B) . However, in C3H/HeN mice not treated with anti-IL-18 Ab, endogenous IL-18 can stimulate Th1 cells to increase IFN-␥ production, causing peak NO production at 2 weeks after infection (Fig. 4B) .
To further substantiate the protective role of endogenous IL-18, we infected IL-18 Ϫ/Ϫ mice with the highly resistant C57BL/6 background with L. major. Although they needed a longer period to achieve cutaneous-lesion resolution, they eventually healed, suggesting that endogenous IL-18 partially contributes to the host defense. In contrast, IL-12-deficient mice suffer from progressive disease (29) . Thus, IL-12 is essential for host defense, while IL-18 is not essential but may contribute to host defense mechanisms by hastening the period required for wound healing through the action to augment IFN-␥ production.
Lymphocytes from wild-type mice and IL-18-deficient mice during infection showed comparable potentialities to produce IFN-␥ in response to SLA or ConA in vitro (Fig. 5B) , further indicating that Th1 cell development occurs without IL-18 in vivo. These results also strongly indicate that Th1 cells can produce IFN-␥ without help from IL-18 in response to ConA or SLA in vitro. Exogenous IL-18 can up-regulate NO production (Fig. 5A) , possibly by augmentation of IFN-␥ production in vivo. Moreover, IL-18 may also increase IFN-␥ production by NK cells at early stages of infection or by antigen-specific CD8 ϩ T cells, which are known to be involved in the resistance to reinfection (12) . As IL-18 deficient mice responded very poorly to reinfection (Fig. 5C) , it is very intriguing to speculate on involvement of IL-18-stimulated CD8 ϩ T cells in the memory response.
Recently, Wei et al. have reported that IL-18 Ϫ/Ϫ mice (129/ Sv ϫ C57BL/6) are highly susceptible to L. major infection. Their IL-18 Ϫ/Ϫ mice showed more apparent footpad swelling and more progressively developing lesions that become ulcerous at 40 days after infection (54) . They reported decreased levels of IFN-␥ in their IL-18 Ϫ/Ϫ mice infected with L. major substrain LV39 (MRHO/SU/59/P), suggesting involvement of IL-18 in stimulation of Th1 cells in vivo. These investigators showed an impaired Th1 response (54) . However, the IL-18 Ϫ/Ϫ mice that we used showed no such impairment (Fig. 4C) . We have used IL-18 Ϫ/Ϫ mice (C57BL/6) which were backcrossed for eight generations onto C57BL/6 mice. We also tested IL-18 Ϫ/Ϫ mice (129/Sv ϫ C57BL/6) (data not shown). Compared with IL-18 ϩ/ϩ mice, both types of IL-18 Ϫ/Ϫ mice showed longlasting footpad swelling (Fig. 5A , upper panel, and data not shown). Indeed, IL-18 Ϫ/Ϫ mice had a higher level of parasite burden than wild-type mice at 5 weeks after infection (data not shown). However, both types of IL-18 Ϫ/Ϫ mice achieved complete lesion resolution at 15 weeks after infection without ulceration. Thus, our results differ from those of Wei et al. in several respects. Although there are many possibilities that account for this discrepancy, this difference may be explained by the difference between L. major substrain LV39 (MRHO/ SU/59/P), used by Wei et al. (54) , and MHOM/SU/73-5-ASKH, used by us. We assume that the LV39 (MRHO/SU/59/P) strain may be more virulent than MHOM/SU/73-5-ASKH, which we used. Alternatively, the MHOM/SU/73-5-ASKH strain may be more susceptible to NO than LV39 (MRHO/SU/59/P). Differences in susceptibility to L. major substrains have also been observed in IL-4R-deficient mice (31) .
Thus, the absence of IL-18 partially influenced the host defense against primary infection (Fig. 5A) . We also tested the role of endogenous IL-18 in host resistance against secondary infection. We found that IL-18 Ϫ/Ϫ mice failed to show an appropriate secondary immune response (Fig. 4C) . These results suggest that endogenous IL-18 contributes to the induction and/or activation of memory cells against L. major infection.
